[Effect of human recombinant granulocyte colony-stimulating factor on mouse hematopoietic and lymphoid organs].
Experiments on intact CBA/CALac mice demonstrated that single (1.25 mg/kg) and repeated (0.125 and 1.25 mg/kg, 30 days) injections of recombinant human granulocyte colony stimulation factor lead to reversible dose-dependent granulocyte lineage hyperplasia in bone marrow, regenerative neutrophilic leukocytosis, and thrombocytosis in peripheric blood and to splenic granulo-, erythro-, and thrombocytopoiesis more expressed in males.